Netherton’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Netherton’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of BCX17725 Safety and Effects in Healthy People and Patients with Netherton Syndrome https://clinicaltrials.eu/trial/a-study-of-bcx17725-safety-and-effects-in-healthy-people-and-patients-with-netherton-syndrome/ Wed, 29 Apr 2026 15:08:02 +0000 https://clinicaltrials.eu/trial/a-study-of-bcx17725-safety-and-effects-in-healthy-people-and-patients-with-netherton-syndrome/ This study involves people with Netherton Syndrome, a rare genetic skin condition that causes red, scaly, and inflamed skin along with severe itching. The condition is caused by changes in a specific gene called SPINK5, which leads to problems with the skin’s protective barrier. People with this condition often experience ongoing skin inflammation and discomfort that can significantly affect their daily lives.

The treatment being tested is called BCX17725, which is an experimental medication given as an injection either into a vein, under the skin, or into a muscle. This medication is designed to work by blocking a specific protein that is overactive in people with Netherton Syndrome and contributes to the skin problems. The purpose of the study is to evaluate how safe and well-tolerated BCX17725 is when given to people with Netherton Syndrome, to measure how the body processes the medication, and to see if it has the potential to improve the skin condition.

During the study, participants will receive BCX17725 for 12 weeks. The study will include both adults and adolescents between the ages of 12 and 65 years who have been diagnosed with Netherton Syndrome. Throughout the study, doctors will monitor participants for any side effects and will assess changes in their skin condition using various scoring systems that measure the severity of scaling, redness, and itching. Blood samples will be taken to measure the amount of medication in the body over time, and skin samples may be collected using strips. Participants will need to attend regular study visits and complete questionnaires about their symptoms.

]]> Study on the Safety and Effectiveness of SXR1096 Cream for Patients with Netherton Syndrome https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-sxr1096-cream-for-patients-with-netherton-syndrome/ Wed, 29 Apr 2026 14:26:28 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-sxr1096-cream-for-patients-with-netherton-syndrome/ This clinical trial is focused on studying Netherton syndrome, a rare genetic skin disorder. The treatment being tested is a cream called SXR1096, which is applied directly to the skin. This cream is designed to target specific proteins in the skin that are involved in the symptoms of Netherton syndrome. The purpose of the study is to evaluate the safety and effectiveness of the SXR1096 cream compared to a placebo in patients with this condition.

The study will involve participants using the cream for a period of time, with regular check-ups to monitor their health and the condition of their skin. Participants will apply the cream to affected areas of their skin, and researchers will assess any changes in their symptoms. The study aims to determine if the cream can improve the skin condition and reduce symptoms such as redness, scaling, and itching.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study will also measure various aspects of skin health, such as the severity of skin symptoms and the skin’s moisture levels. This research is important for understanding how SXR1096 cream can help people with Netherton syndrome and potentially improve their quality of life.

]]> Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome https://clinicaltrials.eu/trial/study-to-evaluate-the-effectiveness-of-spesolimab-in-treating-patients-with-netherton-syndrome/ Wed, 29 Apr 2026 14:24:29 +0000 https://clinicaltrials.eu/trial/study-to-evaluate-the-effectiveness-of-spesolimab-in-treating-patients-with-netherton-syndrome/ This clinical trial is focused on studying a rare skin condition known as Netherton syndrome. This condition is a genetic disorder that affects the skin, hair, and immune system, often leading to red, scaly skin and other complications. The trial is testing a treatment called spesolimab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific targets in the body, potentially helping to treat certain diseases.

The purpose of this study is to evaluate how well spesolimab works in treating patients with Netherton syndrome. Participants in the study will receive either spesolimab or a placebo. The medication will be administered in two forms: as a solution for infusion, which is given through a vein, and as a solution for injection, which is given under the skin. The study will last for a period of time, during which participants will receive the treatment and be monitored for any changes in their condition.

Throughout the study, researchers will observe the participants to see if there is an improvement in their skin condition, such as a reduction in redness and scaling. They will also monitor for any side effects or adverse reactions to the treatment. The goal is to determine if spesolimab is a safe and effective treatment option for people with Netherton syndrome.

]]> Study on the Safety of DS-2325a for Patients with Netherton Syndrome https://clinicaltrials.eu/trial/study-on-the-safety-of-ds-2325a-for-patients-with-netherton-syndrome/ Wed, 29 Apr 2026 14:23:55 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-ds-2325a-for-patients-with-netherton-syndrome/ This clinical trial is focused on studying Netherton Syndrome, a rare genetic skin disorder. The study is testing a potential new treatment called DS-2325a, which is a type of biological medicine known as a fusion protein. The trial will also use a placebo for comparison. The main goal of the study is to explore the safety and tolerability of DS-2325a in patients with Netherton Syndrome.

Participants in the study will receive either the new treatment or a placebo through injections or infusions. The study will monitor participants for any side effects and gather information on how the body processes the treatment. This includes checking for any reactions at the injection site, changes in vital signs like blood pressure and heart rate, and results from blood and urine tests. The study will also look at how the treatment affects the skin and overall quality of life for those with Netherton Syndrome.

The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased. The study will continue for a set period, during which participants will have regular check-ups and assessments to track their progress and any changes in their condition.

]]>